Medical devices are regulated according to the same legislation as food and pharmaceuticals, under the general organization of the Food and Drug Administration (FDA). Manufacturers of high-risk devices such as heart valves and intraocular lens transplants have to demonstrate their safety and effectiveness before the devices can enter the market. One drawback is that many companies who develop these devices find the regulatory process to be very conservative, risk-averse, slow, and expensive. Other organizations concerned with medical practice such as the National Academy of Medicine argue that the current pre-marketing procedures of the FDA are not comprehensive enough. Many devices are cleared for marketing because they are proven to be "substantially similar" to devices already on the market.
The FDA began reviewing food and drugs in 1906 under the original Pure Foods and Drugs Act and gradually added biological products and medical devices as well as radiation-emitting products. Congress continued to expand the purview of the FDA in protecting and promoting drugs, biological products, and medical devices.
The development of the regulatory function of the FDA proceeded according to the following timeline.
This legislation evolved through several updates, including a Medical User Fee and Modernization Act of 2002. This modernization act established user fees for application reviews and set performance targets to keep review times reasonable.
The way the FDA's review works is fairly simple. Each device is classified into one of three classes. The classes are be based on the risk associated with the device.
The actual testing capacity of the FDA is comparatively weak. It is focused on getting medical devices to market as quickly as possible. The FDA relies on the sites that make use of these devices to report any adverse events to the FDA and the manufacturer. These reports are stored in a searchable database for public review. According to the Safe Medical Devices Act of 1990, The FDA began post-market surveillance, conducting inspections and requiring manufacturers of high-risk devices to conduct post-approval studies which could trigger recalls.